Last month (May 2025), Novo Nordisk and Septerna, a San Francisco, California-based bio/pharmaceutical company focused on GCPRs, formed an exclusive global collaboration and license agreement to discover, develop, and commercialize oral small-molecule medicines for treating obesity, Type 2 diabetes, and other cardiometabolic diseases, in a deal worth up to $2.2 billion ($200 million upfront and near-term funding and $2 billion in milestone payments)
Fu LH, Qi C, Liu YJ, Cao WT, Ma MG (2018) Sonochemical synthesis of cellulose/hydroxyapatite nanocomposites and their application in protein adsorption
However, practical considerations exist
Our holistic and integrative approach ensures that we consider all aspects of our patients' well-being in developing personalized treatment plans
Wegovy is the first such drug to receive FDA approval for that purpose, and analysts expect that at least some Medicare Part D plans will cover it